A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMolnlycke Health Care AB

About this trial

The goal of this clinical trial to follow the progress of wounds in those with chronic venous leg ulcers while using a non-bordered foam dressing. The main objective is to follow the progress of these wounds over time from initial visit to each follow-up visit.

Participants will be asked to wear the dressing for up to 6 weeks of treatment or until healed, changed at every one-week interval.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Signed consent to participate (including consent for digital imaging)

Adult aged ≥18 years

Diagnosed with a chronic, exuding VLU

Exudate amount moderate to large

Disqualifiers

Infected ulcer according to the judgment of the investigator defined as any wound condition requiring the prescription or continuation of systemic antibiotic therapy at enrollment

Circumferential wound

Known allergy/hypersensitivity to the materials of the dressing

Use of wound fillers

Trial design

Design model

Single group

Treatments tested in this trial

  • ALLEVYN Non-Adhesive

    Device

    ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction. ALLEVYN Non-Adhesive consists of the following layers: * Breathable top film * Highly absorbent foam core * Non-adhesive wound contact layer

Treatment groups

20 Participants
are divided into 1 treatment group
Group A: Supportive Care with Non-Bordered Foam DressingExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Wound progress of the total effect of treatment using ALLEVYN Non-Adhesive

Wound progress is the total effect of treatment using ALLEVYN Non-Adhesive as the absorbent dressing and includes the changes in an objectively measured wound area and subjectively evaluated wound condition by the treating investigator/designee. Wound progress will be assessed as deteriorated, no change, improved, or healed at each visit. Wound area will be measured by an independent evaluator assisted by digital software at each visit and recorded as cm2 using the formula, A= π\*L\*W/4.

Time frame
From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.

Secondary outcomes

1

Percentage wound area reduction over time

The percentage of wound area (cm2) reduction over time will be assessed by a formula as the area of an ellipse and measured by an independent evaluator assisted by digital software on all digital photographs taken at each scheduled visit.

Time frame
From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
2

Linear wound healing over time

The linear wound healing will be calculated with Gilman's formula (cm/day), G = - (A1-A0)/ {\[(P1+P0)/2\]\*(t1-t0)}, where: A0 = previous visit area A1 = current visit area P0 = previous visit perimeter P1 = current visit perimeter t0 = previous visit time t1 = current visit time. Area (A) and Perimeter (P) will be assessed by an independent evaluator assisted by digital software. Perimeter (P) will be measured in cm and Area (A) will be assessed in cm2.

Time frame
From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
3

Change in granulation tissue over time

The area of wound covered by granulation tissue, (%) before and after cleansing/debridement will be assessed as follows: 1) via an independent evaluator assisted by digital software; and 2) via visual judgement by investigator/designee and determined as: None, 1%-24%, 25%-49%, 50%-74%, or 75%-100%.

Time frame
From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.
4

Change in sloughy tissue over time

The area of wound covered by sloughy tissue, (%) before and after cleansing/debridement will be assessed as follows: 1) via an independent evaluator assisted by digital software; and 2) via visual judgement by investigator/designee and determined as: None, 1%-24%, 25%-49%, 50%-74%, or 75%-100%.

Time frame
From baseline visit to last follow-up visit, a maximum total treatment period of 44 days or until healed, whichever occurs first.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.